0000950170-24-043842.txt : 20240411 0000950170-24-043842.hdr.sgml : 20240411 20240411211041 ACCESSION NUMBER: 0000950170-24-043842 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231214 FILED AS OF DATE: 20240411 DATE AS OF CHANGE: 20240411 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Loew Caroline CENTRAL INDEX KEY: 0001989488 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41837 FILM NUMBER: 24839817 MAIL ADDRESS: STREET 1: MURAL ONCOLOGY LTD. STREET 2: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mural Oncology plc CENTRAL INDEX KEY: 0001971543 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 BUSINESS PHONE: 353 1 905 8020 MAIL ADDRESS: STREET 1: 10 EARLSFORT TERRACE CITY: DUBLIN 2 STATE: L2 ZIP: D02 T380 FORMER COMPANY: FORMER CONFORMED NAME: Mural Oncology Ltd DATE OF NAME CHANGE: 20230403 FORMER COMPANY: FORMER CONFORMED NAME: Pistachiovale Ltd DATE OF NAME CHANGE: 20230329 4/A 1 ownership.xml 4/A X0508 4/A 2023-12-14 2023-12-18 0001971543 Mural Oncology plc MURA 0001989488 Loew Caroline C/O MURAL ONCOLOGY PLC 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 IRELAND true true false false Chief Executive Officer false Stock Option (right to buy) 5.4809 2023-12-14 4 A false 379690 A 2033-07-02 Ordinary Shares 379690 379690 D This amendment to Form 4 is being filed solely to correct the exercise price of the granted option, which was previously reported as being $3.61 due to a scrivener's error. Represents an option award originally granted by Alkermes plc ("Alkermes") that was converted into an option award of Mural Oncology plc (the "Issuer") in connection with the spin-off of the Issuer from Alkermes. This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer. /s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew 2024-04-11